Quantifying the Human Influence on Fire Ignition Across the Western USA

Humans have a profound effect on fire regimes by increasing the frequency of ignitions. Although ignition is an integral component of understanding and predicting fire, to date fire models have not been able to isolate the ignition location, leading to inconsistent use of anthropogenic ignition proxies. Here, we identified fire ignitions from the Moderate Resolution Imaging Spectrometer (MODIS) Burned Area Product (2000–2012) to create the first remotely sensed, consistently derived, and regionally comprehensive fire ignition data set for the western United States. We quantified the spatial relationships between several anthropogenic land-use/disturbance features and ignition for ecoregions within the study area and used hierarchical partitioning to test how the anthropogenic predictors of fire ignition vary among ecoregions. The degree to which anthropogenic features predicted ignition varied considerably by ecoregion, with the strongest relationships found in the Marine West Coast Forest and North American Desert ecoregions. Similarly, the contribution of individual anthropogenic predictors varied greatly among ecoregions. Railroad corridors and agricultural presence tended to be the most important predictors of anthropogenic ignition, while population density and roads were generally poor predictors. Although human population has often been used as a proxy for ignitions at global scales, it is less important at regional scales when more specific land uses (e.g., agriculture) can be identified. The variability of ignition predictors among ecoregions suggests that human activities have heterogeneous impacts in altering fire regimes within different vegetation types and geographies

FATORES DE RISCO CARDIOVASCULAR EM ESTAGIÁRIOS E FUNCIONÁRIOS DA CLÍNICA-ESCOLA DA UNIVERSIDADE ESTADUAL DE GOIÁS

Uma das principais causas de morbimortalidade na sociedade atual são as Doenças Cardiovasculares. Os fatores de riscos podem ser diferentes em determinados países, assim como o seu impacto. Por esta razão, é imprescindível um estudo que possa avaliar os causadores das Doenças Cardiovasculares para aplicação de políticas de saúde para a prevenção dessas doenças. O objetivo do estudo foi investigar entre os estagiários e funcionários da Clínica-Escola da Universidade Estadual de Goiás a prevalência e multiplicidade dos fatores de risco para Doenças Cardiovasculares. O estudo foi do tipo corte transversal com amostra de 78 indivíduos, sendo realizadas avaliações biométricas, mensuração da pressão arterial e aplicação de questionário. A pesquisa demonstrou que o fator de risco de maior prevalência foi a hereditariedade onde 91,1% dos indivíduos apresentaram antecedentes familiares, de primeiro e segundo grau, com eventos cardiovasculares. O segundo fator de risco de maior prevalência foi o sedentarismo totalizando 69,3%, seguido pela obesidade central totalizando 50% dos indivíduos. Verificou-se que 41,1% dos indivíduos consomem bebidas alcoólicas; 24,5% encontram-se na faixa de pré-obeso, obeso I e obeso II. E os fatores de risco com menor prevalência foi a hipertensão arterial e o tabagismo totalizando 6,5% e 2,7%, respectivamente. Considera-se que é necessário levantar o perfil de risco para as Doenças Cardiovasculares da população, e assim compreender esses fatores de risco, pois estão diretamente relacionados com a gênese, a progressão e a ocorrência de futuros eventos cardiovasculares. E posteriormente apresentar propostas para a realização de uma prevenção com foco individual, institucional e governamental

Density of reef sharks estimated by applying an agent-based model to video surveys

Policies on harvesting and conservation are developed in response to information about trends in the abundance of species, so making accurate estimates of abundance is important. However, estimating the abundance of sparsely distributed species is challenging, especially where direct observations are difficult. We collected observations of blacktip reef sharks Carcharhinus melanopterus by using remote underwater video cameras, and developed an agent-based model to generate estimates of the density of sharks from the frequency of observations made using the video. We augmented these observations with diel patterns in detections in different habitats of C. melanopterus with surgically implanted acoustic transmitters. Median estimates of density ranged from 2-9 ind. km-2 at noon to 20-90 ind. km-2 at dusk, depending on whether modelled movement paths were random or directional. These estimates suggest that individuals might exhibit diel patterns in movement, with directional movement to the reef flat during dusk. Data from tagged individuals supported this hypothesis, with more detections recorded from reef flat habitat during early evening and early morning than at other times of day. Estimates of density were among the highest reported for C. melanopterus. The agent-based model approach is flexible, and can be extended to simulate a range of behaviours and other types of observations

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study

Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to identify the best threshold of serum golimumab before drug intensification predictive of response.Patients and methods: We included all consecutive patients with active UC with loss of response to golimumab in a prospective multicentric cohort study. Patients with loss of response at 50 mg q4 weeks (W) and 100 mg q4W underwent therapeutic intensification at 100 mg q4W and 100 mg q2W, respectively. Effectiveness and safety were assessed between Weeks 2 and 4 (visit 2) and between Weeks 4 and 8 (visit 3) after intensification. Serum level and anti-golimumab antibodies were evaluated at each medical visit (Lisa Tracker, Theradiag France).Results: A total of 47 UC patients (Female, 50%; median age, 39 years (IQR, 27-52)) treated with golimumab for a median of 20.4 weeks (IQR, 10.7-38.3) were included. The median partial Mayo score was 6 (IQR, 5-7), and the median endoscopic Mayo score was 3 (IQR, 2-3). The median golimumab serum level before intensification was 2.23 μg/mL (IQR, 1.02-3.96) and only one patient (2.1%) had anti-drug antibodies. At Visit 2 (Week 2-4), 40% patients experienced clinical response, 10% clinical remission, 33% endoscopic response and 23% endoscopic remission. At Visit 3 (Week 4-8), 44% of patients had clinical response, 22% of patients had clinical remission, 45% of patients had endoscopic response, and 41% of patients had endoscopic remission. The median golimumab levels before intensification do not differ between responders and non-responders (2.13 μg/ml (0.76-2.76) and 3.37 μg/ml (IQR, 1.08-4.67), respectively; p = 0.14) assessed at Visit 3. Golimumab intensification to 100 mg q4W (vs q2W) (OR 1.98, 95% CI [1.06-3.70]; p = 0.032) was significantly associated with clinical remission at Visit 3. Serum drug level at baseline or the presence of antidrug antibodies were not associated with clinical or endoscopic remission/response. Two serious adverse events (one infection and one UC flare) were reported during the 24-week follow-up.Conclusion: In this prospective multicentric study, half of patients recaptured response following golimumab intensification in UC. Therapeutic drug monitoring did not predict response after optimisation of golimumab

Multitemporal and multiresolution leaf area index retrieval for operational local rice crop monitoring

This paper presents an operational chain for high-resolution leaf area index (LAI) retrieval from multiresolution satellite data specifically developed for Mediterranean rice areas. The proposed methodology is based on the inversion of the PROSAIL radiative transfer model through the state-of-the-art nonlinear Gaussian process regression (GPR) method. Landsat and SPOT5 data were used for multitemporal LAI retrievals at high-resolution. LAI estimates were validated using time series of in situ LAI measurements collected during the rice season in Spain and Italy. Ground LAI data were collected with smartphones using PocketLAI, a specific phone application for LAI estimation. Temporal evolution of the LAI estimates using Landsat and SPOT5 data followed consistently the temporal evolution of the in situ LAI measurements acquired on several Mediterranean rice varieties. The estimates had a root-mean-square-error (RMSE) of 0.39 and 0.51 m2/m2 in Spain and 0.38 and 0.47 m2/m2 in Italy for Landsat and SPOT5 respectively, with a strong correlation (R2 > 0.92) for both cases. Spatial-temporal assessment of the estimated LAI from Landsat and SPOT5 data con- firmed the robustness and consistency of the retrieval chain. This paper demonstrates the importance of an adequate characterization of the underlying rice background in order to address changes in background condition related to water management. Results highlight the potential of the proposed chain for deriving multitemporal near real-time decametric LAI maps fundamental for operational rice crop monitoring, and demonstrate the readiness of the proposed method for the processing of data such as the recently launched Sentinel-

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study

Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to identify the best threshold of serum golimumab before drug intensification predictive of response.Patients and methods: We included all consecutive patients with active UC with loss of response to golimumab in a prospective multicentric cohort study. Patients with loss of response at 50 mg q4 weeks (W) and 100 mg q4W underwent therapeutic intensification at 100 mg q4W and 100 mg q2W, respectively. Effectiveness and safety were assessed between Weeks 2 and 4 (visit 2) and between Weeks 4 and 8 (visit 3) after intensification. Serum level and anti-golimumab antibodies were evaluated at each medical visit (Lisa Tracker, Theradiag France).Results: A total of 47 UC patients (Female, 50%; median age, 39 years (IQR, 27-52)) treated with golimumab for a median of 20.4 weeks (IQR, 10.7-38.3) were included. The median partial Mayo score was 6 (IQR, 5-7), and the median endoscopic Mayo score was 3 (IQR, 2-3). The median golimumab serum level before intensification was 2.23 μg/mL (IQR, 1.02-3.96) and only one patient (2.1%) had anti-drug antibodies. At Visit 2 (Week 2-4), 40% patients experienced clinical response, 10% clinical remission, 33% endoscopic response and 23% endoscopic remission. At Visit 3 (Week 4-8), 44% of patients had clinical response, 22% of patients had clinical remission, 45% of patients had endoscopic response, and 41% of patients had endoscopic remission. The median golimumab levels before intensification do not differ between responders and non-responders (2.13 μg/ml (0.76-2.76) and 3.37 μg/ml (IQR, 1.08-4.67), respectively; p = 0.14) assessed at Visit 3. Golimumab intensification to 100 mg q4W (vs q2W) (OR 1.98, 95% CI [1.06-3.70]; p = 0.032) was significantly associated with clinical remission at Visit 3. Serum drug level at baseline or the presence of antidrug antibodies were not associated with clinical or endoscopic remission/response. Two serious adverse events (one infection and one UC flare) were reported during the 24-week follow-up.Conclusion: In this prospective multicentric study, half of patients recaptured response following golimumab intensification in UC. Therapeutic drug monitoring did not predict response after optimisation of golimumab

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study

Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to identify the best threshold of serum golimumab before drug intensification predictive of response.Patients and methods: We included all consecutive patients with active UC with loss of response to golimumab in a prospective multicentric cohort study. Patients with loss of response at 50 mg q4 weeks (W) and 100 mg q4W underwent therapeutic intensification at 100 mg q4W and 100 mg q2W, respectively. Effectiveness and safety were assessed between Weeks 2 and 4 (visit 2) and between Weeks 4 and 8 (visit 3) after intensification. Serum level and anti-golimumab antibodies were evaluated at each medical visit (Lisa Tracker, Theradiag France).Results: A total of 47 UC patients (Female, 50%; median age, 39 years (IQR, 27-52)) treated with golimumab for a median of 20.4 weeks (IQR, 10.7-38.3) were included. The median partial Mayo score was 6 (IQR, 5-7), and the median endoscopic Mayo score was 3 (IQR, 2-3). The median golimumab serum level before intensification was 2.23 μg/mL (IQR, 1.02-3.96) and only one patient (2.1%) had anti-drug antibodies. At Visit 2 (Week 2-4), 40% patients experienced clinical response, 10% clinical remission, 33% endoscopic response and 23% endoscopic remission. At Visit 3 (Week 4-8), 44% of patients had clinical response, 22% of patients had clinical remission, 45% of patients had endoscopic response, and 41% of patients had endoscopic remission. The median golimumab levels before intensification do not differ between responders and non-responders (2.13 μg/ml (0.76-2.76) and 3.37 μg/ml (IQR, 1.08-4.67), respectively; p = 0.14) assessed at Visit 3. Golimumab intensification to 100 mg q4W (vs q2W) (OR 1.98, 95% CI [1.06-3.70]; p = 0.032) was significantly associated with clinical remission at Visit 3. Serum drug level at baseline or the presence of antidrug antibodies were not associated with clinical or endoscopic remission/response. Two serious adverse events (one infection and one UC flare) were reported during the 24-week follow-up.Conclusion: In this prospective multicentric study, half of patients recaptured response following golimumab intensification in UC. Therapeutic drug monitoring did not predict response after optimisation of golimumab

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study

Introduction: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to identify the best threshold of serum golimumab before drug intensification predictive of response.Patients and methods: We included all consecutive patients with active UC with loss of response to golimumab in a prospective multicentric cohort study. Patients with loss of response at 50 mg q4 weeks (W) and 100 mg q4W underwent therapeutic intensification at 100 mg q4W and 100 mg q2W, respectively. Effectiveness and safety were assessed between Weeks 2 and 4 (visit 2) and between Weeks 4 and 8 (visit 3) after intensification. Serum level and anti-golimumab antibodies were evaluated at each medical visit (Lisa Tracker, Theradiag France).Results: A total of 47 UC patients (Female, 50%; median age, 39 years (IQR, 27-52)) treated with golimumab for a median of 20.4 weeks (IQR, 10.7-38.3) were included. The median partial Mayo score was 6 (IQR, 5-7), and the median endoscopic Mayo score was 3 (IQR, 2-3). The median golimumab serum level before intensification was 2.23 μg/mL (IQR, 1.02-3.96) and only one patient (2.1%) had anti-drug antibodies. At Visit 2 (Week 2-4), 40% patients experienced clinical response, 10% clinical remission, 33% endoscopic response and 23% endoscopic remission. At Visit 3 (Week 4-8), 44% of patients had clinical response, 22% of patients had clinical remission, 45% of patients had endoscopic response, and 41% of patients had endoscopic remission. The median golimumab levels before intensification do not differ between responders and non-responders (2.13 μg/ml (0.76-2.76) and 3.37 μg/ml (IQR, 1.08-4.67), respectively; p = 0.14) assessed at Visit 3. Golimumab intensification to 100 mg q4W (vs q2W) (OR 1.98, 95% CI [1.06-3.70]; p = 0.032) was significantly associated with clinical remission at Visit 3. Serum drug level at baseline or the presence of antidrug antibodies were not associated with clinical or endoscopic remission/response. Two serious adverse events (one infection and one UC flare) were reported during the 24-week follow-up.Conclusion: In this prospective multicentric study, half of patients recaptured response following golimumab intensification in UC. Therapeutic drug monitoring did not predict response after optimisation of golimumab